This study aims to evaluate whether SGLT2 inhibitors can modulate the occurrence of VT or supraventricular tachycardias (SVTs) in HFrEF patients with an implanted defibrillator. The gene discussed is SLC5A2; the disease is Supraventricular tachycardia.